Kristine A. Moore

Kristine A. Moore

Auto-generated profile, based on publicly available information

Kristine A. Moore

Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Vaccine
Verified
Journal Article
Open access
KMKristine A. Moore
Kristine A. Moore
JOJulia T. Ostrowsky
Julia T. Ostrowsky
AKAlison M. Kraigsley
Alison M. Kraigsley
AMAngela J. Mehr
Angela J. Mehr
JBJoseph S. Bresee
Joseph S. Bresee
JWJerry Weir
Jerry Weir
Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.

1 July 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
KMKristine A Moore
Kristine A Moore
AMAngela J Mehr
Angela J Mehr
JOJulia T Ostrowsky
Julia T Ostrowsky
AUAngela K Ulrich
Angela K Ulrich
NMNicolina M Moua
Nicolina M Moua
MOMichael T Osterholm
Michael T Osterholm

1 July 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
KMKristine A Moore
Kristine A Moore
JOJulia T Ostrowsky
Julia T Ostrowsky
AMAngela J Mehr
Angela J Mehr
RJRebecca A Johnson
Rebecca A Johnson
AUAngela K Ulrich
Angela K Ulrich
MOMichael T Osterholm
Michael T Osterholm

21 February 2023 in Vaccine
Verified
Journal Article
Open access
KMKristine A. Moore
Kristine A. Moore
TLTabitha Leighton
Tabitha Leighton
JOJulia T. Ostrowsky
Julia T. Ostrowsky
CACory J. Anderson
Cory J. Anderson
RDRichard N. Danila
Richard N. Danila
MOMichael T. Osterholm
Michael T. Osterholm
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.

15 October 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LBLisa M Brosseau
Lisa M Brosseau
KEKevin Escandón
Kevin Escandón
AUAngela K Ulrich
Angela K Ulrich
Angela L. RasmussenAngela L. Rasmussen
Angela L. Rasmussen
Chad J RoyChad J Roy
Chad J Roy
MOMichael T Osterholm
Michael T Osterholm
The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dose, infection, and coronavirus disease 2019 (COVID-19) outcomes remains poorly understood. This review summarizes the existing literature regarding this issue, identifies gaps in current knowledge, and suggests opportunities for future research. In humans, host characteristics, including age, sex, comorbidities, smoking, and pregnancy, are associated with severe COVID-19. Similarly, in animals, host factors are strong determinants of disease severity, although most animal infection models manifest clinically with mild to moderate respiratory disease. The influence of variants of concern as it relates to infectious dose, consequence of overall pathogenicity, and disease outcome in dose–response remains unknown. Epidemiologic data suggest a dose–response relationship for infection contrasting with limited and inconsistent surrogate-based evidence between dose and disease severity. Recommendations include the design of future infection studies in animal models to investigate inoculating dose on outcomes and the use of better proxies for dose in human epidemiology studies.

1 July 2025 in Vaccine
Verified
Journal Article
Open access
JOJulia T Ostrowsky
Julia T Ostrowsky
NVNatalie C Vestin
Natalie C Vestin
AMAngela J Mehr
Angela J Mehr
AUAngela K Ulrich
Angela K Ulrich
LBLauren Bigalke
Lauren Bigalke
ITInfluenza Vaccines R And D Roadmap Taskforce
Influenza Vaccines R And D Roadmap Taskforce
Influenza vaccines that provide more effective immunity to seasonal influenza as well as protection against a broad range of emerging influenza viruses with pandemic potential are needed to reduce the public-health burden of influenza and enhance pandemic preparedness. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was published in 2021 to serve as a strategic planning tool to advance influenza vaccine R&D. Following IVR publication, a 3-year monitoring, evaluation, and adjustment (ME&A) program was implemented to assess progress in meeting the milestones outlined in the IVR. As of mid-May 2025, 16 (17%) of the 93 milestones had been accomplished or partially accomplished, with the majority (67; 72%) in various stages of progress. Of the 35 milestones designated high-priority, five (14%) had been accomplished or partially accomplished, 29 (83%) are in progress, and no progress was identified for one (3%). Key accomplishments include: establishing longitudinal cohort studies to characterize immune responses to influenza virus infection and vaccination by age over time and by vaccine product; creating a comprehensive landscape of innovative influenza vaccine technologies in preclinical and clinical development; advancing next-generation and broadly protective influenza vaccine candidates into clinical trials; identifying relevant lessons learned from accelerated SARS-CoV-2 vaccine development during the COVID-19 pandemic; and initiating development of a full value of improved influenza vaccine assessment (FVIVA) to inform investment and guide the eventual uptake of improved vaccines globally. Persistent challenges include clarifying immune mechanisms for generating durable and broadly protective immunity, enhancing understanding of immune imprinting and the role of mucosal immunity in preventing infection and transmission, identifying correlates of protection, and exploring regulatory options for broadly protective influenza vaccine licensure. The IVR ME&A program provides a basis for ongoing critical review of progress in influenza vaccine R&D to inform decision-making on research priorities and funding.